Calcitriol Capsule
NDC Package 65162-576-10
Package Information
Calcitriol capsules is predialysis PatientsCalcitriol capsules re indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. This formulation utilizes a capsule delivery system. Marketed by Amneal Pharmaceuticals Llc, this product is identified by NDC 65162-576 and is authorized under FDA application ANDA203289.
Identification & Billing
- RxCUI: 308867 - calcitriol 0.25 MCG Oral Capsule
- RxCUI: 308867 - calcitriol 0.00025 MG Oral Capsule
- RxCUI: 308868 - calcitriol 0.5 MCG Oral Capsule
- RxCUI: 308868 - calcitriol 0.0005 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 65162 - Amneal Pharmaceuticals Llc
- 65162-576 - Calcitriol
- 65162-576-10 - 100 CAPSULE in 1 BOTTLE
- 65162-576 - Calcitriol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (65162-576). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65162-576-10 identifies a specific commercial package of 100 capsule in 1 bottle of Calcitriol, a human prescription drug labeled by Amneal Pharmaceuticals Llc. This capsule is formulated for oral use and contains calcitriol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amneal Pharmaceuticals Llc on June 18, 2017. The current certification is valid through December 31, 2027.
How is this Amneal Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65162057610. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.